Angiotensin II Trial NCT01679132 Marked Completed as of Sept 2026

A clinical trial update dated September 11, 2026 lists the BAROSTIM NEO Hypertension Pivotal Trial, registered as NCT01679132, with a status of completed. The trial phase is listed as not applicable. Angiotensin II is named as a compound associated with this study record. The trial registry does not provide results data alongside this status change. No efficacy or safety outcomes are included in this update, and none should be inferred from a completed status alone. The update reflects only that the trial has reached its completed stage as of the listed date, according to the registry entry. No additional detail on enrollment, endpoints, or findings is included in the event data provided. Readers should note that a completed status refers to the trial's operational stage, not to any reported result. Angiotensin II remains an approved compound, and this update does not change that regulatory status. For further context on this compound, including its approved uses and background, readers can consult the compound overview.